Searching... Searching...
  • NVP + NA
  • Köp NA
  • Sälj NA
  • Senast NA
  • SEK

  • NEVPF +NA
  • Buy NA
  • Sell NA
  • Latest NA
  • USD

About us

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly.​​

The company is focused on two projects. KL1333, a powerful NAD+ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development.

Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

  • Press Releases

    Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures 08 October Abliva AB (Nasdaq Stockholm: ABLI) today announces that M... Read More